Loading...

Merck & Co Inc
NYSE:MRK

Watchlist Manager
Merck & Co Inc Logo
Merck & Co Inc
NYSE:MRK
Watchlist
Price: 104.12 USD +1.15% Market Closed
Updated: Feb 6, 2023

Intrinsic Value

The intrinsic value of one MRK stock under the Base Case scenario is 111.13 USD. Compared to the current market price of 104.12 USD, Merck & Co Inc is Undervalued by 6%.

The Intrinsic Value is calculated as the average of the two valuation methods:

MRK Intrinsic Value
Base Case
111.13 USD
Undervaluation 6%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Fundamental Analysis

MRK Profitability Score
Profitability Due Diligence

Merck & Co Inc's profitability score is 69/100. The higher the profitability score, the more profitable the company is.

Declining ROE
Positive Revenue Growth Forecast
ROIC is Increasing
Positive 1-Year Revenue Growth
69/100
Profitability
Score

Merck & Co Inc's profitability score is 69/100. The higher the profitability score, the more profitable the company is.

MRK Solvency Score
Solvency Due Diligence

Merck & Co Inc's solvency score is 74/100. The higher the solvency score, the more solvent the company is.

Positive Net Debt
Short-Term Liabilities
Long-Term Liabilities
Low D/E
74/100
Solvency
Score

Merck & Co Inc's solvency score is 74/100. The higher the solvency score, the more solvent the company is.

Financials
Efficiency
72%
Gross Margin
34%
Operating Margin
24%
Net Margin
26%
FCF Margin
35%
ROE
19%
ROIC
Other

MRK Capital Structure
Merck & Co Inc

Market Capitalization 264B USD
Total Debt 28.5B USD
Minority Interest 66M USD
Preferred Equity 0 USD
Cash and Equivalents 11.1B USD
Short-Term Investments 103M USD
Enterprise Value 281B USD

Wall St
Price Targets

MRK Price Targets Summary
Merck & Co Inc

Wall Street analysts forecast MRK stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MRK is 118.59 USD with a low forecast of 101 USD and a high forecast of 141.75 USD.

Lowest
Price Target
101 USD
3% Downside
Average
Price Target
118.59 USD
14% Upside
Highest
Price Target
141.75 USD
36% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

MRK Competitors
Merck & Co Inc

MRK Suppliers & Customers
Merck & Co Inc

Merck & Co Inc has 120 key suppliers from 13 countries and 16 industries. The majority of these suppliers are located in the United States of America, with the largest number of suppliers in the Biotechnology industry.

United States of America
71
Veeva Systems Inc
Health Care
Johnson & Johnson
Pharmaceuticals
Emergent BioSolutions Inc
Biotechnology
Omnicom Group Inc
Media
A
Argan Inc
Construction
ChargePoint Holdings Inc
Electrical Equipment
Ampco-Pittsburgh Corp
Metals & Mining
Bristol-Myers Squibb Co
Pharmaceuticals
Model N Inc
Technology
Pros Holdings Inc
Technology
Pfizer Inc
Pharmaceuticals
Alexandria Real Estate Equities Inc
Real Estate
O
ON24 Inc
Technology
Aptargroup Inc
Packaging
Gilead Sciences Inc
Biotechnology
Upland Software Inc
Technology
Ligand Pharmaceuticals Inc
Biotechnology
Fulcrum Therapeutics Inc
Pharmaceuticals
Cue Biopharma Inc
Biotechnology
OpGen Inc
Biotechnology
PDS Biotechnology Corp
Biotechnology
9
908 Devices Inc.
Electrical Equipment
NGM Biopharmaceuticals Inc
Pharmaceuticals
Aligos Therapeutics Inc
Biotechnology
Heska Corp
Health Care
Sellas Life Sciences Group Inc
Biotechnology
Liquidity Services Inc
Retail
Schrodinger Inc
Health Care
Surface Oncology Inc
Biotechnology
Foghorn Therapeutics Inc.
Biotechnology
E
Eiger BioPharmaceuticals Inc
Biotechnology
Grid Dynamics Holdings Inc
Technology
Advaxis Inc
Biotechnology
Neoleukin Therapeutics Inc
Biotechnology
Iteos Therapeutics Inc
Biotechnology
Certara Inc
Health Care
ALX Oncology Holdings Inc
Biotechnology
Guardant Health Inc
Health Care
Oncorus Inc
Biotechnology
Progress Software Corp
Technology
Personalis Inc
Life Sciences Tools & Services
bluebird bio Inc
Biotechnology
Moderna Inc
Biotechnology
Sutro Biopharma Inc
Biotechnology
Transcat Inc
Trading Companies & Distributors
Cocrystal Pharma Inc
Pharmaceuticals
Chinook Therapeutics Inc
Biotechnology
A
Avalo Therapeutics Inc
Biotechnology
Aeglea Bio Therapeutics Inc
Biotechnology
Evelo Biosciences Inc
Biotechnology
Myriad Genetics Inc
Biotechnology
SCYNEXIS Inc
Pharmaceuticals
Codexis Inc
Life Sciences Tools & Services
Vaccinex Inc
Biotechnology
A
AvePoint Inc
Technology
Illumina Inc
Life Sciences Tools & Services
Leap Therapeutics Inc
Biotechnology
X
Xilio Therapeutics Inc
Biotechnology
Yumanity Therapeutics Inc
Biotechnology
Rapt Therapeutics Inc
Biotechnology
Lumos Pharma Inc
Biotechnology
Atara Biotherapeutics Inc
Biotechnology
OncoSec Medical Inc
Biotechnology
Agenus Inc
Biotechnology
N
Nugenerex Immuno-Oncology Inc
N/A
Paul Mueller Co
Machinery
TetraLogic Pharmaceuticals Corp
Biotechnology
Enzon Pharmaceuticals Inc
Biotechnology
G
Generex Biotechnology Corp
Biotechnology
Seagen Inc
Biotechnology
Microstrategy Inc
Technology
Suppliers Map

Merck & Co Inc has 60 key customers from 9 countries and 7 industries. The majority of these customers are located in the United States of America, with the largest number of customers in the Biotechnology industry.

Customers Map

Ownership

MRK Insider Trading
Buy and sell transactions by insiders

Merck & Co Inc insiders have only sold shares in the past 12 months.

During the last 12 months Merck & Co Inc insiders have not bought any shares, and sold 301M USD worth of shares. The last transaction was made on Feb 6, 2023 by Chattopadhyay Sanat (Exe V-P & Pres. MMD), who sold 9.4M USD worth of MRK shares.

Sold
0-3
months
58.3M USD
5
3-6
months
242M USD
7
6-9
months
0 USD
0
9-12
months
0 USD
0
Bought
0-3
months
0
0 USD
3-6
months
0
0 USD
6-9
months
No Insider Transactions
0
0 USD
9-12
months
No Insider Transactions
0
0 USD
Cumulative Transactions Amount
Period Sold Bought Net
3 Months
58.3M USD
N/A
-58.3M
6 Months
301M USD
N/A
-300.7M
9 Months
301M USD
N/A
-300.7M
12 Months
301M USD
N/A
-300.7M
Purchases
13
Sales
188
No transactions found
Why is insider trading important?

Shareholder Return

MRK Price
Merck & Co Inc

1M 1M
-9%
6M 6M
+19%
1Y 1Y
+38%
3Y 3Y
+40%
5Y 5Y
+128%
Annual Price Range
104.12
52w Low
71.69
52w High
114.84
Price Metrics
Average Annual Return 14.85%
Standard Deviation of Annual Returns 22.2%
Max Drawdown -10%
Shares Statistics
Market Capitalization 264B USD
Shares Outstanding 2 542 000 000
Percentage of Shares Shorted 0.77%

Company Profile

Merck & Co Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

264B USD

Dividend Yield

2.7%

Description

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company is headquartered in Kenilworth, New Jersey and currently employs 68,000 full-time employees. The firm offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. The company operates through two segments: Pharmaceutical and Animal Health. The firm's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The firm sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species.

Contact

NEW JERSEY
Kenilworth
2000 Galloping Hill Rd
+19087404000.0
https://www.merck.com/

IPO

1941-01-01

Employees

68 000

Officers

CEO & Chairman
Mr. Robert M. Davis J.D.
Exec. VP & CFO
Ms. Caroline Litchfield
Exec. VP & Pres of Merck Animal Health
Mr. Richard R. DeLuca Jr.
Exec. VP & Pres of Merck Research Laboratories
Dr. Dean Y. Li M.D., Ph.D.
Exec. VP and Chief Information & Digital Officer
Mr. David Michael Williams
VP of Investor Relations
Mr. Peter Dannenbaum
Show More
Exec. VP & Gen. Counsel
Ms. Jennifer L. Zachary
Sr. VP and Chief Ethics & Compliance Officer
Lisa LeCointe-Cephas
VP of Global Communications
Ms. Jennifer Mauer
Exec. VP and Chief Communications & Public Affairs Officer
Ms. Cristal N. Downing
Show Less

See Also

Similar Stocks
What is the Intrinsic Value of one MRK stock?

The intrinsic value of one MRK stock under the Base Case scenario is 111.13 USD.

Is MRK stock undervalued or overvalued?

Compared to the current market price of 104.12 USD, Merck & Co Inc is Undervalued by 6%.